Therachon gets US FDA orphan drug status for apraglutide for short bowel syndrome treatment

Therachon AG, a clinical─stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, announced that the US Food and Drug

More From BioPortfolio on "Therachon gets US FDA orphan drug status for apraglutide for short bowel syndrome treatment"